SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$18.9 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 263.09% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.9 million (down 65.91% YoY) and the FY2025 annual result came in at -$73.6 million, down 115.78% from the prior year.
• Net Income towards Common Stockholders fell to -$18.9 million in Q1 2026, from -$15.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $985863.0 in Q1 2022 to a low of -$22.9 million in Q4 2023.
• A 5-year average of -$9.2 million and a median of -$7.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 845.93% — and 2024, when it soared 50.15%.
• Tracing SABS's Net Income towards Common Stockholders over 5 years: stood at -$7.9 million in 2022, then plunged by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then slumped by 32.8% to -$15.1 million in 2025, then decreased by 24.7% to -$18.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$18.9 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.8 million (Q3 2025), per Business Quant data.